AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a weekThe FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the Share XAZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a weekhttps://pharmaphorum.com/news/azs-enhertu-gains-second-breakthrough-tag-in-space-of-a-week/
Daiichi Sankyo: pharma needs to become NHS ‘experts’If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership Share XDaiichi Sankyo: pharma needs to become NHS ‘experts’https://pharmaphorum.com/views-analysis-market-access/daiichi-sankyo-pharma-needs-to-become-nhs-experts/
Current pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadAt eyeforpharma Daiichi Sankyo’s Manuel Reiberg spoke about why the industry should look to make drugs more affordable Share XCurrent pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadhttps://pharmaphorum.com/news/current-pharma-model-not-sustainable-during-covid-19-says-daiichis-uk-lead/
Antibody-drug conjugates on the marchOne of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal Share XAntibody-drug conjugates on the marchhttps://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filingThe FDA has approved an advanced breast cancer drug from AstraZeneca and Daiichi Sankyo in super-quick time. The Share XFDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filinghttps://pharmaphorum.com/news/fda-hastily-approves-daiichi-sankyo-azs-cancer-drug/
AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseaseAstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Share XAZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseasehttps://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalatesBig-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and Share XDaiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalateshttps://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/
Astellas gets EU approval for AML drug XospataThe European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia Share XAstellas gets EU approval for AML drug Xospatahttps://pharmaphorum.com/news/astellas-gets-eu-approval-for-aml-drug-xospata/
AZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewThe FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, Share XAZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewhttps://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/
